We are live on ! Find out more
TE

Tema ETFs Portfolio holdings

AUM $3.09B
1-Year Est. Return 72.72%
This Fund
S&P 500
This Quarter Est. Return
-2.81%
1 Year Est. Return
+72.72%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$335M
AUM Growth
+$93.9M
Cap. Flow
+$112M
Cap. Flow %
33.58%
Top 10 Hldgs %
28.51%
Holding
174
New
26
Increased
81
Reduced
34
Closed
27

Top Buys

Rank Stock Value
1
TEX icon
Terex
TEX
+$6.33M
2
HRI icon
Herc Holdings
HRI
+$6.32M
3
TKR icon
Timken Company
TKR
+$4.82M
4
BMY icon
Bristol-Myers Squibb
BMY
+$4.37M
5
VMC icon
Vulcan Materials
VMC
+$4.35M

Top Sells

Rank Stock Value
1
PRIM icon
Primoris Services
PRIM
+$7.13M
2
FLR icon
Fluor
FLR
+$5.32M
3
FSS icon
Federal Signal
FSS
+$5.11M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$2.53M
5
ASND icon
Ascendis Pharma A/S
ASND
+$1.85M

Sector Composition

Rank Sector Weight
1 Industrials 43.38%
2 Healthcare 33.02%
3 Utilities 7.31%
4 Technology 5.91%
5 Financials 4.26%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IDXX icon
101
Idexx Laboratories
IDXX
$44.8B
$748K 0.22%
1,781
+1,045
+142% +$454K
DAWN
102
DELISTED
Day One Biopharmaceuticals
DAWN
$723K 0.22%
91,123
+5,362
+6% +$57.8K
NRIX icon
103
Nurix Therapeutics
NRIX
$2.4B
$703K 0.21%
59,146
+36,589
+162% +$612K
CGON icon
104
CG Oncology
CGON
$6.34B
$701K 0.21%
28,612
+20,283
+244% +$571K
INSM icon
105
Insmed
INSM
$23.5B
$700K 0.21%
9,181
-1,445
-14% -$111K
TECH icon
106
Bio-Techne
TECH
$11.2B
$660K 0.2%
11,252
+5,328
+90% +$361K
CBOE icon
107
Cboe Global Markets
CBOE
$28.6B
$537K 0.16%
+2,375
New +$493K
BDX icon
108
Becton Dickinson
BDX
$43.6B
$516K 0.15%
2,252
+1,330
+144% +$309K
MIRM icon
109
Mirum Pharmaceuticals
MIRM
$7.25B
$515K 0.15%
11,432
-30,536
-73% -$1.44M
WST icon
110
West Pharmaceutical
WST
$25.3B
$508K 0.15%
2,269
-911
-29% -$251K
FTNT icon
111
Fortinet
FTNT
$118B
$503K 0.15%
+5,222
New +$529K
ALGN icon
112
Align Technology
ALGN
$12.7B
$486K 0.15%
+3,059
New +$600K
AKRO
113
DELISTED
Akero Therapeutics
AKRO
$477K 0.14%
11,778
-20,372
-63% -$863K
ELVN icon
114
Enliven Therapeutics
ELVN
$3.8B
$465K 0.14%
+23,648
New +$509K
VKTX icon
115
Viking Therapeutics
VKTX
$4.31B
$464K 0.14%
19,231
-984
-5% -$31.1K
IMCR icon
116
Immunocore
IMCR
$1.78B
$458K 0.14%
15,428
+4,234
+38% +$127K
TEVA icon
117
Teva Pharmaceuticals
TEVA
$37.3B
$444K 0.13%
28,861
+3,199
+12% +$57.1K
GH icon
118
Guardant Health
GH
$20.7B
$433K 0.13%
10,160
-25,960
-72% -$1.12M
NBIX icon
119
Neurocrine Biosciences
NBIX
$17.2B
$432K 0.13%
3,904
+58
+2% +$7.35K
COGT icon
120
Cogent Biosciences
COGT
$6.68B
$429K 0.13%
71,563
+19,637
+38% +$154K
LNTH icon
121
Lantheus
LNTH
$7B
$423K 0.13%
4,329
-3,633
-46% -$340K
ZYME icon
122
Zymeworks
ZYME
$1.78B
$393K 0.12%
+33,001
New +$450K
GPCR icon
123
Structure Therapeutics
GPCR
$3.45B
$391K 0.12%
22,590
-21,753
-49% -$533K
ARWR icon
124
Arrowhead Research
ARWR
$10.5B
$381K 0.11%
29,893
-31,610
-51% -$575K
REPL icon
125
Replimune Group
REPL
$859M
$366K 0.11%
+37,522
New +$464K
3 4
5
6 7

Similar funds

DCM
Donaldson Capital Management Evansville, Indiana $3.09B AUM 21.24% 1-Year Est. Return
HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
KF
Krilogy Financial St. Louis, Missouri $3.11B AUM 20.67% 1-Year Est. Return
TCG
Tremblant Capital Group West Palm Beach, Florida $3.11B AUM 18.12% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
CAM
Contour Asset Management New York $3.08B AUM 21.94% 1-Year Est. Return
VBA
Van Berkom & Associates Montreal, Quebec, Canada $3.08B AUM 12.07% 1-Year Est. Return
FI
Focused Investors Los Angeles, California $3.08B AUM 12.02% 1-Year Est. Return

Tema ETFs's Q1 2025 Portfolio in Review

As of Q1 2025, Tema ETFs held 174 positions worth $335M, up 39% from $241M the previous quarter. Its ten largest holdings account for 29% of the portfolio.

Tema ETFs deployed $112M of net new capital in Q1 2025, opening 26 new positions and adding to 81 existing holdings. Its largest new stake was Bristol-Myers Squibb: 75,050 shares worth $4.58M.

By sector, the portfolio is most concentrated in Industrials at 43% of assets, down from 46% a quarter earlier, followed by Healthcare and Utilities.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $2.53M trimmed.

  • Tema ETFs's largest Q1 2025 buy was Bristol-Myers Squibb: 75,050 shares worth $4.58M.
  • Tema ETFs added most to Terex in Q1 2025, an estimated $6.33M increase.
  • Tema ETFs's biggest Q1 2025 reduction was Alnylam Pharmaceuticals, cutting an estimated $2.53M.
  • Tema ETFs fully exited Primoris Services in Q1 2025, selling an estimated $7.13M.
  • Tema ETFs's ten largest holdings make up 29% of its $335M portfolio in Q1 2025.
  • Tema ETFs opened 26 new positions and closed 27 in Q1 2025.
  • Tema ETFs's portfolio value rose 39% quarter-over-quarter to $335M.

Based on Tema ETFs's 13F filing for Q1 2025, filed 14 May 2025.